ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: However, imatinib resistance in CML is not necessarily caused by BCR-ABL mutations and CML patients who escape to imatinib therapy frequently express a non mutated form of BCR-ABL [4].